The role of SRPX1 in cerebral amyloid angiopathy
Description: Several molecules have reportedly co-accumulated with tissue amyloid deposits in patients with amyloidosis. Co-accumulating molecules may be a key-molecule in amyloidosis therapy and diagnosis. In CAA, however, molecules that co-accumulate with cerebrovascular Aβ deposits are unknown. To identify the key molecules in CAA, we used laser capture microdissection to perform proteomic analyses with cerebral blood vessels obtained from CAA cases. Last year, we reported highly expressed co-accumulating molecules in CAA-affected vessels derived from human brain samples. The present study proposal focuses on Enzyme X, a highly up-regulated molecule in CAA in our prior research. We found that Enzyme X inhibits Amyloid beta fibril formation, degrades Aß fibrils, and attenuates Amyloid beta-mediated cytotoxicities. From these results, we hypothesized that Enzyme X may be a novel therapeutic target for CAA and AD.
Amount: ¥2,730,000
Funding type: fellowship
Funder scheme: Grant-in-Aid for Research Activity Start-up
Start date: 2017-08-25
End date: 2019-03-31
Investigator: Yasuteru Inoue
Institution: Kumamoto University
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 3
Funder award ID: 17H06972
OpenAlex ID: G5409760487